Today: 19 May 2026
FTSE 100 hits 10,000 after best year since 2009
2 January 2026
2 mins read

FTSE 100 hits 10,000 after best year since 2009

NEW YORK, January 2, 2026, 03:53 ET

  • The FTSE 100 hit the 10,000 level for the first time on Friday after a near-22% rise in 2025
  • Miners, defence firms and banks led gains as the index beat the STOXX 600 and S&P 500 last year
  • LSEG data showed the benchmark logged 41 record closes in 2025 and ended the year at 9,931

Britain’s FTSE 100 hit the 10,000 level for the first time on Friday, capping a surge that left the index up nearly 22% in 2025, its strongest annual showing since 2009. The benchmark beat both the pan-European STOXX 600 and the U.S. S&P 500 last year, while the more domestically focused FTSE 250 rose about 9%. Miners such as Fresnillo, defence contractors including Babcock and Rolls-Royce and banks led by Lloyds powered gains in a market with limited exposure to artificial intelligence (AI) stocks.

The milestone follows a year in which the FTSE 100 logged 41 all-time high closes, with the most recent record on Dec. 30, data from London Stock Exchange Group (LSEG) showed. The index — a benchmark of the 100 biggest companies on the London Stock Exchange, heavy in banks, miners and oil and gas — finished 2025 at 9,931 points, up 21.5% from the start. Germany’s DAX climbed 21.5% and the S&P 500 gained 17% in 2025, while the pan-European STOXX 600 was up nearly 16%, Sky News reported.

Investors have pointed to the index’s sector mix and a push by companies to return cash to shareholders. FTSE 100 members make about three-quarters of their combined revenues overseas, helping insulate the benchmark from the UK economy, Guardian columnist Nils Pratley wrote. Sue Noffke, head of UK equities at Schroders, said, “The UK stock market has moved on from being the dividend yield capital of the world,” arguing that share buybacks now play a larger role. The Guardian

The FTSE 100 is often described as a blue-chip index, meaning it is dominated by large, established companies. It is weighted by market value, so the biggest firms have the most influence on daily moves.

That structure makes currency moves important. When a company earns much of its revenue abroad but reports in pounds, sterling swings can amplify or reduce those overseas earnings when translated back into UK currency.

Share buybacks are one way companies deploy surplus cash. In a buyback, a company repurchases its own shares, reducing the share count and often boosting earnings per share.

The rally also underlined how different London looks from markets dominated by technology. The FTSE’s heavy exposure to commodities, defence and financials means it can rise on different drivers than an AI-led tech boom.

That contrast showed up in year-end comparisons. U.S. gains leaned heavily on a handful of mega-cap tech names, while London’s gains were spread across sectors more tied to metal prices, defence demand and interest-rate settings.

For UK investors, the gap between the internationally focused FTSE 100 and the more UK-sensitive FTSE 250 has remained a key signal. A stronger run in the large-cap index can reflect global revenue streams more than domestic conditions.

The 10,000 milestone also arrives as fund managers reset portfolios for the new year. Investors will be watching whether the same mix of commodities, defence-related demand and bank profitability keeps underpinning returns.

Stock Market Today

  • When Will Island Pharmaceuticals Limited (ASX:ILA) Reach Profitability?
    May 19, 2026, 3:26 AM EDT. Island Pharmaceuticals Limited (ASX:ILA), a drug repurposing company focusing on antiviral therapeutics in Australia and the U.S., posted a AU$3.9 million loss in the latest financial year and a AU$7.2 million loss over the trailing twelve months. Analysts project the company will break even in 2027 and reach a profit of AU$295 million by 2028. This forecast implies an ambitious average annual growth rate of 140%. Notably, Island Pharmaceuticals operates with no debt, relying solely on shareholder funding, which reduces financial risk typical in cash-burning pharmaceutical firms. Investors anticipate milestone developments but should remain cautious of the high growth assumptions given the volatile nature of pharmaceutical cash flows during drug development phases.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Tesla stock today: TSLA watched ahead of quarterly delivery report after Musk gift filing
Previous Story

Tesla stock today: TSLA watched ahead of quarterly delivery report after Musk gift filing

Bitcoin price today rises toward $90,000 as ETF flows and Fed bets steer sentiment
Next Story

Bitcoin price today rises toward $90,000 as ETF flows and Fed bets steer sentiment

Go toTop